Compare TG Therapeutics Inc (TGTX) vs TJX Companies Inc (TJX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs TJX Companies Inc — how do they compare? TG Therapeutics Inc trades at $54 (market cap $8.26B), while TJX Companies Inc trades at $154.6 (market cap $172.00B). The key difference: TJX Companies Inc is far larger — about 20.8× TG Therapeutics Inc's market cap, and TJX Companies Inc pays a 1.23% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | TJX | |
|---|---|---|
Market Cap | $8.26B | $172.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $59.06 | $168.41 |
52-Week Low | $26.39 | $124.53 |
Enterprise Value | $8.50B | $180.60B |
Dividend Yield | — | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TJX trades at $155.00, up 0.4% on the day, with a bullish technical outlook supported by moving averages and strong fundamental performance. The company reported revenue of $56.36 billion in 2025 with a net income margin of 9.4%, and has consistently beaten EPS estimates in recent quarters. Recent news highlights TJX as a beneficiary of shifting retail trends and economic uncertainty.
The outlook for TJX remains positive, driven by earnings growth, international expansion, and strong analyst support with a consensus price target of $181.80. Key risks include competitive pressures in discount retail and sensitivity to consumer spending fluctuations, but the company's robust cash flow and dividend payments provide stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
